Definition

A preparation of autologous, ex vivo-expanded, CD4- and CD8-positive T lymphocytes specific for six tumor-associated antigens (TAAs), with potential immunomodulating and antineoplastic activities. Upon administration of six TAAs-specific autologous T cells MT-601, the T cells target, bind to and induce selective toxicity in cancer cells overexpressing one or more of these six TAAs. By targeting more than one antigen, MT-601 may be able to induce a better and more durable anti-tumor response due to its ability to overcome antigen loss.